Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
Status:
Terminated
Trial end date:
2017-08-17
Target enrollment:
Participant gender:
Summary
This study will be conducted in three parts. Part A is a dose-escalation study to determine
two safe and tolerable doses of ASN001 for men with metastatic castration resistant prostate
cancer. Part A will also characterize the pharmacokinetics and pharmacodynamics of the ASN001
through blood sampling. Subjects in Part B will receive one of two doses identified in Part A
to determine which one is more effective, and collect additional pharmacokinetic data. Part C
is an extension for subjects completing either Part A or B.